Table 2.
First author/Study | Primary Endpoint/objective | Place | n | Targeted agents | Inhibition of molecular pathways | PHASE | STAGE/PATIENTS | Comments |
---|---|---|---|---|---|---|---|---|
Herbst et al 2011 (BeTa) |
OS | USA | 636 | bevacizumab plus erlotinib vs erlotinib alone | EGFR + VEGFR | III | recurrent or refractory/pretreated 1st line treatment | not improved OS |
Papadimitrakopoulou et al 2012 | feasible dosages of combination therapy | Greece | 94 | erlotinib + everolimus as 2nd and 3rd line | EGFR + mTOR | I | refractory advanced/pretreated platinum-taxanes based CT | acceptable tolerability and disease control |
Scagliotti et al 2012 | OS | Italy | 960 | Sunitinib Plus Erlotinib | EGFR + VEGFR | III | Pretreated/ at least one platinum-based regimen | significantly longer PFS and greater ORR |
Boutsikou et al 2013 | OS | Greece | 229 | erlotinib and/or bevacizumab | EGFR + VEGFR | III | IIIb/IV non-squamous/ pretreated docetaxel-carboplatin | promising but not improved OS |
Falchook et al 2013 | Evaluation of this combination treatment for the first time | USA | 34 | erlotinib, cetuximab, and bevacizumab | EGFR + VEGFR | I | advanced/pretreated | well-tolerated, antitumor activity |